Brenntag SE (BNR)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 62.00 |
|---|---|
| 52-week range | 43.72 – 66.86 |
| Return, 1 month / 3 months | +3.0% / +4.9% |
| Return, 1 year / 3 years | +25.9% / +0.8% |
| Trend | Uptrend |
| RSI (14) | 51 |
| Volatility (1 year) | 28.7% |
| Worst drawdown (1 year) | -24.5% |
| Average daily value traded | 15.10M EUR |
| Dividend yield | 3.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Brenntag SE is a chemical distribution company based in Essen, Germany. It buys chemicals and ingredients from producers and supplies them to manufacturers and other business customers, offering a broad range of industrial and specialty chemicals along with related services such as mixing, blending, packaging and logistics. Its customers come from many sectors, including pharmaceuticals, food, personal care, coatings, water treatment and industrial manufacturing, and it serves these markets through a network of distribution sites in many countries.
On this site Brenntag SE appears as a stock on the XETRA Stock Exchange (Germany), code BNR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Brenntag SE (BNR) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 62.00 on 22 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 64 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.9% and over the last three months it rose 4.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 9.7% | ||
| From 52-week high | -4.7% | ||
| Momentum | 70 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 4.9% | ||
| 6-month return | 6.3% | ||
| 12-month return, skipping the last month | 22.3% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.5% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 15.10M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 55 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −4.3% |
|---|---|
| 1 month | +3.0% |
| 3 months | +4.9% |
| 6 months | +6.3% |
| 1 year | +25.9% |
| 3 years | +0.8% |
| 5 years | −13.0% |
Signals
| 50-day / 200-day average | 61.17 / 56.53 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.31 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 May 2026 | EUR 1.9000 |
| 23 May 2025 | EUR 2.1000 |
| 24 May 2024 | EUR 2.1000 |
| 16 Jun 2023 | EUR 2.0000 |
| 10 Jun 2022 | EUR 1.4500 |
| 11 Jun 2021 | EUR 1.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.